Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1880
http://purl.obolibrary.org/obo/NCIT_C1880
|
|---|---|
| Preferred Name | Canertinib Dihydrochloride |
| Definitions |
The hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents. |
|---|---|
| prefLabel | Canertinib Dihydrochloride
|
| label | Canertinib Dihydrochloride
|
| PDQ_Closed_Trial_Search_ID | 38403
|
| code | C1880
|
| Has_Target | |
| prefixIRI | NCIT:C1880
|
| in_subset |
See more
See less
|
| Display_Name | Canertinib Dihydrochloride
|
| Preferred_Name | Canertinib Dihydrochloride
|
| FDA_UNII_Code | ICJ93X8X90
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C24H25ClFN5O3.2HCl
|
| Maps_To | Canertinib Dihydrochloride
|
| CAS_Registry | 289499-45-2
|
| NCI_Drug_Dictionary_ID | 38403
|
| Legacy Concept Name | CI-1033
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of some types of cancer. Canertinib blocks the action of proteins called epidermal growth factor receptors, and may cause cancer cells to die. It is a type of tyrosine kinase inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38403
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C1707132
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |